In CRISPR Patent Dispute, the Federal Circuit Clarifies the Conception and Written Description Standards READ MORE
Settled Expectations: How the PTAB’s New Discretionary Denial Framework Is Reshaping IPR Strategy READ MORE
Regeneron Pharmaceuticals, Inc. v. Amgen Inc.: Jury Finds Rebate Offers on Bundled Drugs in Exchange for Exclusive Formulary Placement Violate Antitrust Laws READ MORE
Federal Circuit Provides Further Guidance on Obvious Type Double Patenting For Patents Sharing Common Priority READ MORE
